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Summary
In this review we summarize the essential findings about
the function of tumour necrosis factor (TNF) and its
cognate receptors TNFR1 and TNFR2, and lymphotoxin α
(LT-α) ligands in immune-mediated CNS inflammation
and demyelination. The advent of homologous
recombination technology in rodents provides a new
method which has been used during the last 5 years and
has led to insights into the pathophysiology of
experimental autoimmune encephalomyelitis (EAE) in an
unprecedented way. Studies with knockout mice in which
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Introduction
The myelin sheath that enfolds many of the larger axons in
the CNS is formed by oligodendrocytes. Selective myelin
loss occurs in apparently very different diseases of the CNS
and the mechanisms of demyelination are various. Loss of
myelin may be due to damage of myelin, for example by
toxins, or result from impairment of oligodendrocyte function
and survival. Demyelination is one of the hallmarks of
experimental autoimmune encephalomyelitis (EAE), an
inflammatory disease of the CNS that serves as an animal
model for multiple sclerosis. EAE can be induced in a number
of genetically susceptible animal species by immunization
with myelin or the myelin components, including myelin
basic protein (MBP), proteolipid protein and myelin
oligodendrocyte glycoprotein (MOG) (for review, see
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genes of the TNF ligand/receptor superfamily are not
expressed and studies with transgenic mice overexpressing
TNF and TNFR reveal the critical role of the TNFR1
signalling pathway in the control of CNS demyelination
and inflammation. These studies provide novel findings
and at the same time shed light on the complex
pathophysiology of EAE. Together, these findings may
contribute to better understanding of EAE and open new
avenues in experimental therapies for multiple sclerosis.
Wekerle et al., 1994). Several essential features of human
multiple sclerosis are reflected in MOG-induced EAE: the
chronic, relapsing clinical disease course, and the
pathohistological triad of inflammation, reactive gliosis and
the formation of large, confluent demyelinated plaques with a
topographical distribution similar to that in multiple sclerosis.
EAE can be transferred by MBP-, proteolipid protein- or
MOG-specific T cells that express CD4 (a marker of T-helper
cells) and produce interferon γ (IFN-γ) but little interleukin
(IL) 4, IL-10 or TGF-β (transforming growth factor β) (for
review, see Olsson, 1995). As a consequence of the invasion
of the CNS by such autoreactive T-helper 1 cells, the
perivascular macrophages and glial cells, including
intraparenchymal microglia cells and astrocytes, become
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activated. The induction of demyelination, however, is more
complicated. Depending upon the genetic background of the
animals and the properties of the autoantigen, demyelination
is induced by different immunological effector mechanisms.
In rats and primates little demyelination is observed when
the disease is induced by adoptive transfer of myelin-specific
CD4 T cells. Massive demyelination ensues when, in
addition to the encephalitogenic T-cell response,
demyelinating anti-MOG antibodies are present in the lesions
(Linington et al., 1988; Storch et al., 1998; Genain et al.,
1999). In contrast, demyelinated plaques can be induced in
mice in the absence of a demyelinating antibody response:
B-cell-deficient mice develop a chronic form of EAE with
early onset of disease and pronounced demyelination (Eugster
et al., 1998; Hjelmstrom et al., 1998). Furthermore, nitric
oxide can be excluded as a crucial effector molecule in
demyelination because inactivation of the inducible nitric
oxide synthase gene in mice immunized with MOG does not
prevent T-cell-mediated demyelination (Sahrbacher et al.,
1998).
First data supporting a role for TNF-α and
LT-α in the aetiopathogenesis of CNS
inflammation and demyelination
Tumour necrosis factor (TNF)-α and lymphotoxin (LT)-α are
both considered to be proinflammatory, cytotoxic cytokines
(Appendix I) and critical mediators of inflammatory,
autoimmune pathologies such as multiple sclerosis and EAE.
Evidence comes from four types of experiments. First, these
cytokines are detectable in lesions of multiple sclerosis and
EAE. In EAE they are identified, together with IFN-γ and
IL-2, at the onset of CNS lesions, but not during repair,
which is paralleled by the predominance of so-called
T-helper 2 (Th-2) cells producing IL-10, IL-4 and TGF-β
(for review, see Olsson, 1995). The encephalitogenicity of
T cells is associated with their ability to synthesize TNF-α
and LT-α (Powell et al., 1990). Apart from being produced
by infiltrating lymphocytes and macrophages, TNF-α and
LT-α are also expressed by activated CNS parenchymal cells,
microglial cells (Frei et al., 1987; Renno et al., 1995) and
astrocytes (Liebermann et al., 1989; Chung and Benenveniste,
1990). The capacity for TNF-α expression is much higher
in astrocytes isolated from T-cell-mediated EAE-susceptible
Lewis rats than from resistant Brown Norway rats (Chung
et al., 1991). In multiple sclerosis patients, TNF-α is
overproduced in the serum and cerebrospinal fluid (Sharief
and Hentges, 1991). In lesions, members of the TNF-α ligand
and receptor families are expressed extensively. LT-α is
expressed by lymphocytes and microglia, TNF-α by
microglia/macrophages, occasional astrocytes and endothelial
cells, TNFR1 by oligodendrocytes around lesions, and LTβR
by astrocytes (Hofman et al., 1989; Selmaj et al., 1991;
Canella et al., 1997; Raine et al., 1998). Furthermore, T cells
isolated from multiple sclerosis patients positive for HLA-
DR2 produce significantly more TNF-α and LT-α (but not
IFN-γ) than T cells from DR2– donors (Zipp et al., 1995).
However, none of four polymorphic loci situated at the TNF-
α locus was found to be associated with the incidence of
the relapsing–remitting form of multiple sclerosis (Roth
et al., 1994).
Secondly, further to the well-documented pro-inflammatory
effects of TNF-α and LT-α, including the induction of
adhesion molecules (Bevilacqua, 1993), chemokines (Butcher
et al., 1996) and macrophage activation (Philip and Epstein,
1986), both cytokines can induce selective cytotoxicity of
rodent, bovine and human primary oligodendrocytes and
oligodendrocyte cell lines (Selmaj and Raine, 1988; D’Souza
et al., 1995) and induce myelin damage in CNS slices
(Selmaj and Raine, 1988). They have therefore been directly
implicated in the demyelinating process. This has been a
somewhat controversial issue in culture. When the transfected
oligodendrocyte cell line Oli-neu was used, TNF-α-mediated
cell lysis was observed in immature but not mature cells
(Malipiero et al., 1997). However, in vivo, TNF-α/TNFR1
signalling in the CNS of transgenic mice was shown to
selectively induce the apoptosis of mature myelinating
oligodendrocytes, myelin vacuolation and the development
of primary demyelinating lesions (Akassoglou et al., 1998a).
In addition to affecting oligodendrocyte survival, TNF-α
may also hinder remyelination by augmenting the effect of
IFN-γ in hindering oligodendrocyte development (Agresti
et al., 1996).
Thirdly, direct evidence for the involvement of TNF-α
in chronic EAE comes from in vivo studies. On the one
hand, administration of TNF-α prolongs EAE and induces
relapses (Kuroda and Shimamoto, 1991; Crisi et al., 1995);
on the other hand, blockade of TNF-α and LT-α by
antibodies or TNFR1 preparations prevents or ameliorates
clinical disease (Ruddle et al., 1990; Baker et al., 1994;
Martin et al., 1995; Selmaj et al., 1995; Willenborg et al.,
1995; Klinkert et al., 1997; Korner et al., 1997a).
Amelioration was correlated with substantially reduced
CNS inflammation in some studies (Ruddle et al., 1990;
Martin et al., 1995; Selmaj et al., 1995). Interestingly, in
two other studies a soluble TNFR1–IgG fusion protein
was shown to inhibit clinical symptoms without hindering
cellular infiltration into the CNS (Klinkert et al., 1997;
Korner et al., 1997a), but the activation state of
inflammatory leucocytes and microglia isolated from the
treated animals was found to be reduced (Korner et al.,
1997a). The reason certain anti-TNF-α antibody preparations
result in disease exacerbation remains unclear (Willenborg
et al., 1995), but additional emerging roles for TNF-α in
the suppression of the effector phase of the autoimmune
response may underlie such effects (Appendix I) (for
review, see Cope, 1998).
Are TNF-α, LT-α or both cytokines required
for EAE?
In C57BL/6 mice, sensitization with MOG peptide 35–55
leads to a chronic relapsing inflammatory demyelinating
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Fig. 1 Clinical course of MOG-induced EAE from wild-type, TNF/LT-α–/–, TNFR1–/–, TNFR2–/– and
TNFR1/TNFR2–/– mice. The acute phase of clinical symptoms is clearly controlled either by the
absence of both ligands (TNF-α and LT-α) or by the absence of TNFR1. On the other hand, EAE in
TNFR2–/– mice results in the exacerbation of clinical symptoms during the acute phase of EAE.
Double TNFR1/TNFR2–/– mice had a clinical course similar to that of TNFR1–/– mice. The ascending
paralysis was scored from 0 to 5 (0  no clinical signs; 1  limp tail; 2  partial hind limb paralysis;
3  complete hind limb paralysis; 4  tetraplegia; 5  death). Numbers in parentheses indicate the
total number of animals in study; number remaining at end of study.
disease. Demyelination in this model is independent of
demyelinating antibodies, at least in the initial stages, since
the humoral response to MOG peptide 35–55 does not
recognize intact MOG in vivo. This model is therefore a
good tool to study antibody-independent demyelination in
EAE. Study of the function of TNF-α and LT-α in EAE
became possible with the generation of gene knockout mice.
When immunized with MOG peptide 35–55, mice produced
by backcrossing TNF/LT-α–/– mice onto the C57BL/6
background do not develop an acute disease but show a
slowly progressive form of EAE (Eugster et al., 1999)
(Fig. 1). Clinical symptoms of EAE in rodents (ascending
paralysis) are the consequences of mainly two pathological
features affecting the spinal cord: inflammation (involving
macrophages and T lymphocytes) and demyelination.
Demyelination, however, is not necessarily the predominant
factor in the induction of clinical signs. In our studies with
MOG-induced EAE in C57BL/6 mice, the loss of myelin
follows the initial invasion of lymphocytes and macrophages
and the onset of clinical signs with a delay of more than
1 week. The recruitment of T cells into the CNS of TNF/
LT-α–/– mice was found to be unimpaired, and at later time
points of the disease (day 60 after immunization) was even
increased compared with controls. However, despite the
intense inflammation, only minimal demyelination develops
(Fig. 2A–C) (Eugster et al., 1999). This indicates that the
clinical symptoms of EAE in TNF/LT-α–/– mice are mainly
the result of inflammation. Indeed, the clinical features of
EAE are well known to develop in experimental animals in
the absence of demyelination. This is seen, for example, in
rats with EAE after immunization with myelin autoantigens
or the transfer of myelin-specific T cells (for review, see
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Fig. 2 Demyelination in MOG-induced EAE and TNF transgenic mice depends on the expression of
TNFR1. (A) Large demyelinated areas (arrows) are found in the spinal cord of wild-type animals with
MOG-induced EAE (day 60, Klu¨ver–Barrera luxol fast blue stain, magnification 48). (B and C) In
TNF/LT-α–/– mice with MOG-EAE (day 60), inflammation is prominent (haematoxylin–eosin,
arrowheads), whereas demyelination (C) is minimal (magnification 48). (D) In Tg6074 TNF
transgenic mice (8 weeks old), large demyelinated plaques with periodic acid-Schiff-positive
macrophages are formed in the cerebellum (magnification 99). (E) Tg6074 transgenics on a
TNFR1–/– background, however, do not show pathology (magnification 99).
Wekerle et al., 1994). Numerous in vitro and in vivo studies
have delineated the complicated role of cytokines, oxygen
radicals, nitric oxide and proteases in affecting the integrity
of the blood–brain barrier and in impairing neuronal functions.
The latter role may be due to direct effects on neurones or
may result from effects of the aforementioned molecules on
astrocytes and oligodendrocytes, cells that are critically
involved in the survival and function of neurones.
Controversial data have been published on the effect of
cytokines on neurones. For example, IL-6, which is detected
at the onset of EAE, enhances the response of neurones to
excitatory amino acids, induces the persistence of calcium-
induced calcium release and, upon overexpression in
transgenic animals, leads to neurodegeneration (Holliday
et al., 1995; Qiu et al., 1995; Heyser et al., 1997). IL-1
suppresses the calcium channel current in hippocampal
neurones, and thereby may lead to progression of
neurodegenerative processes (Plata-Salaman and ffrench-
Mullen, 1994). On the other hand, TNF-α, IL-6 and IL-1
have been reported to increase neuronal survival after a toxic
influx of calcium mediated by excitotoxins. The effects of
IL-6 and IL-1 may be due, at least in part, to the induction
of release of neurotrophogenic factors such as nerve growth
factor (Frei et al., 1989; Carlson et al., 1999). The data
available indicate that the clinical symptoms induced by a
low level of demyelination, as seen in TNF/LT-α–/– mice,
may be aggravated by oedema formation due to alterations
of the blood–brain barrier and by abnormal functions of
neurones in inflammatory lesions.
Our recent data have demonstrated that the increase in
T-cell infiltration of the CNS seen in these mice is a result
of impaired elimination of the T cells present in the CNS
tissue. It is known that (i) T-cell apoptosis in the CNS
precedes clinical remission in EAE, and (ii) depending upon
the disease model analysed, Fas ligand (FasL) and/or TNF-α
can mediate the apoptosis of activated T cells. In studying
the different possibilities, it was found that the extent of
T-cell apoptosis is diminished by 50% in EAE lesions of
TNF/LT-α–/– mice (Bachmann et al., 1999). This contrasts
with lpr and gld mice, which have a genetic defect of Fas-
mediated apoptosis and which show no decrease in T-cell
apoptosis in EAE lesions compared with controls (Bachmann
et al., 1999).
The individual roles of TNF-α and LT-α in the effects
seen in TNF/LT-α–/– mice, namely the delay of MOG-induced
EAE, the striking inflammation associated with reduction of
T-cell apoptosis and the limited extent of demyelination, are
now beginning to emerge after intensive research efforts.
A critical requirement for TNF-α in the initiation of the
neurological deficit of EAE has been demonstrated elegantly
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by Sedgwick and co-workers, using MOG peptide 35–55 as
an antigen in TNF-α–/– mice that had been generated directly
on a C57BL/6 genetic background (Korner et al., 1997a).
These mice showed a significant delay (6 days) in the onset
of clinical disease relative to wild-type mice. This delay
correlated with impaired migration of leucocytes within the
CNS and the formation of cuffs. At later time points, disease
was severe and associated with widespread perivascular
inflammation in the CNS, but primary demyelination appeared
to be reduced overall (Korner et al., 1997a). These results
demonstrate that TNF-α plays a unique role in promoting
disease initiation by controlling initial leucocyte movement
within the CNS, possibly through its known effect on the
induction of adhesion molecules and chemokines.
In wild-type mice, TNF-α was already present in the CNS
by day 7 after immunization with MOG 35–55, peaked at
day 20, and then waned. At day 7, TNF-α-producing cells
were predominantly microglia (Juedes et al., 2000). TNF-α
induces expression of T-cell chemokines, including IP-10
(interferon-inducible protein 10) and MCP-1 (monocyte
chemotactic protein 1) in astrocytes. Indeed IP-10, MCP-1
and the chemokine RANTES (regulated upon activation,
normal T-cell expressed and secreted chemokine) were
detected in the CNS by day 8 after immunization with MOG
35–55 (Juedes et al., 2000). These data make it very likely
that TNF-α triggers the expression of chemokines in the
CNS, which leads to invasion by T cells and monocytes. In
the absence of TNF-α in TNF-α/LT-α or in TNF-α gene
knockout mice, invasion of the CNS by immune cells is
delayed, but later develops extensively. This indicates that
other cytokines, such as IFN-γ, may at some time points
compensate for the absence of TNF-α. Indeed, astrocytes
treated with IFN-γ release IP-10, a potent chemokine for
activated but not resting T cells (Oh et al., 1999). In BALB/c
mice with a knockout of the IFN-γ gene, an increase in the
development of EAE was noted, the effect being associated
with induction of the chemokines MCP-1 and GRO-α
(Glabinski et al., 1999). The redundancy of both the signals
inducing chemokine production and the chemokines
activating T cells and monocytes, together with the expression
of chemokine genes in different types of cells, allows
compensation for a single defect in the whole cascade,
leading to invasion of the CNS by inflammatory cells.
Furthermore, genetic influences mediated by both MHC
(major histocompatibility complex) and non-MHC genes play
a significant role.
In a recent study of mice produced by backcrossing
TNF-α–/– animals onto a C57BL/6 background, no delay in
the onset of MOG-induced EAE was evident, but the duration
of disease was prolonged and was paralleled by higher levels
of mononuclear cell infiltrates and extensive demyelination
(Liu et al., 1998). Furthermore, inactivation of the TNF-α
gene converted MOG-resistant mice of the 129/Sv strain to
a state of high susceptibility. This study confirmed that
TNF-α is not an obligatory mediator of inflammation and
demyelination in EAE, but in addition provided the first
evidence for a potent anti-inflammatory role of TNF-α in
limiting the extent and duration of clinical disease. Our
own studies in TNF-α–/– mice (backcrossed onto C57BL/6)
immunized with MOG confirm the data of Sedgwick and co-
workers (Korner et al., 1997a), the difference from wild-
type controls being mainly a delay in disease onset (H. P.
Eugster, K. Frei and H. Fontana, unpublished observation).
Interestingly, the finding that TNF-α is required for the
normal initiation of clinical EAE has been confirmed in a
different EAE model, in which MBP is used as an antigen
to induce CNS inflammation and demyelination in susceptible
SJL mice. Immunization of TNF-α–/– mice on the SJL/J
genetic background, and appropriate SJL (H-2b) congenic
controls with MBP showed a significant delay (5 days) in the
onset of neurological deficits, but the eventual development of
severe EAE with perivascular inflammation and
demyelination was equal to that in controls (Kassiotis
et al., 1999a).
An independent role for LT-α in EAE has been more
difficult to evaluate. An apparently clear picture was painted
in a comparative study in which MOG was used as an
antigen in LT-α–/– and LT-β–/– mice generated initially on a
129  C57BL/6 background and backcrossed at least four
times onto C57BL/6. Whereas LT-β–/– mice developed EAE,
LT-α–/– mice exhibited an EAE-resistant phenotype, and a
major role for homotrimeric LT-α in EAE pathogenesis
was deduced (Suen et al., 1997). A major criticism of
autoimmunity studies using LT-α–/– (LT-α–/– and TNF/LT-α–/–)
and LT-β–/– mice has been that these animals show severe
structural and functional immune deficiencies, including the
absence of lymph nodes and Peyer’s patches, as well as a
disorganized splenic microarchitecture that is associated with
decreased numbers of splenic dendritic cells (De Togni et al.,
1994; Banks et al., 1995; Eugster et al., 1996; Koni et al.,
1997) (Appendix I). Nevertheless, evidence was obtained for
successful MOG-induced T-cell priming in LT-α–/– and LT-
β–/– mice (Suen et al., 1997). TNF/LT-α–/– mice are susceptible
to MOG-induced EAE, demonstrating that, despite severe
immune system abnormalities, primary autoimmunity to
myelin can be induced in these mice (Eugster et al., 1999).
As stated by Steinman and ourselves, however, compensatory
mechanisms may overcome structural and functional
deficiencies in these gene knockout mice (Frei et al., 1997;
Steinman, 1997). Furthermore, gene inactivation-dependent
changes may occur, such as significantly reduced TNF-α
levels in LT-α–/– mice (Alexopoulou et al., 1998). It is
interesting to note here that these animals were found to be
significantly more susceptible than wild-type controls to the
transfer of EAE by T-cell lines or spleen cells from MOG-
immunized mice (Suen et al., 1997). This finding further
supports an anti-inflammatory effect of TNF-α and LT-α
during CNS autoimmunity. The role of LT-α derived from
haemopoiesis (the major source of this cytokine) was
addressed elegantly by the use of bone marrow chimaeras.
Bone marrow from LT-α–/– mice was transferred into
immunodeficient mice in which the recombinase activation
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Table 1 TNFR1-dependent demyelination: evidence from different animal models of disease
Animal model Mouse strain Disease index* Inflammation† Demyelination†
EAE: immunization with MOG Wild-type 347  
peptide 35–55
TNFR1–/– 114  
TNFR2–/– 565  
TNFR1/2–/– 71  
TNF/LT-α–/– 81  
TNF-α–/– 153 () ()
LT-α–/–‡ 61 (560)‡ () –
Tg6074 TNF transgenic mice TNFR1/2/ Ataxia/paralysis  
TNFR1–/– Normal – –
TNFR2–/– Ataxia/paralysis  
*Animals were monitored and weighed daily, and disease severity was scored on a scale from 0 to 5,
with 0.5 points for intermediate clinical findings. The scores were as follows: 0  no detectable signs
of EAE; 1  loss of tail tone; 2  definitive tail and partial hind limb paralysis; 3  hind limb
paralysis; 4  hind and fore limb paralysis; 5  death. The disease index was calculated by adding all
the daily average disease scores (of all animals in a group), dividing by the average day of disease
onset (of all animals in a group) and multiplying by 100. †Histopathology was assessed at day 60 after
immunization with MOG and at 8 weeks in Tg6074 TNF-α transgenic mice. ‡Data from Suen and
colleagues (Suen et al., 1997); disease index calculated at 30 days; control disease index in brackets.
gene Rag-1 had been inactivated. EAE in these mice showed
disease onset, rate of progression and peak severity similar
to those in RAG-1–/– mice that had been reconstituted with
bone marrow from wild-type mice (Rimington et al., 1998).
As a positive control, the transfer of TNF-α–/– bone marrow
into RAG-1–/– recipients delayed the onset of actively induced
EAE and altered the movement of inflammatory leucocytes
within the CNS. These results show that bone marrow-
derived LT-α does not play a unique role in EAE. However,
it remains to be determined whether CNS-specific LT-α,
demonstrated in total RNA from whole CNS by RT–PCR
(reverse transcriptase polymerase chain reaction) (Rimington
et al., 1998), represents a disease-relevant level of LT-α by
parenchymal cells such as astrocytes or resident microglia.
While a specific role for LT-α in EAE remains to be defined,
one possibility is that it can upregulate EAE susceptibility
genes. It may be that EAE in TNF/LT-α–/– mice, which
develop the disease in spite of the absence of LT-α, is due
to loss of the function of TNF-α in suppressing these
undefined, LT-α-controlled EAE susceptibility genes.
Absence of TNFR1 mimics the effect of TNF-α
and LT-α deficiency: inflammation but no
demyelination
TNF-α and LT-α bind as homotrimers to both the TNFR1
(p55 TNF-α receptor) and the TNFR2 (p75 TNF-α receptor)
(Appendix I). On the basis of the observation of a profound
effect of the absence of TNF/LT-α on MOG-induced EAE,
we questioned which of the two TNF-α receptors is involved
in the disease. TNFR2–/– mice develop a chronic form of
EAE with a very severe onset (Fig. 1). It remains to be
determined whether this effect is a direct result of the elevated
TNF-α levels that have been measured in these mice (Peschon
et al., 1998), or whether the TNFR2 can mediate a disease-
protective effect in the presence of a functional TNFR1. The
absence of TNFR2 also results in the absence of soluble
TNFR2, the concentration of which has been shown to
dramatically exceed that of soluble TNFR1 under
inflammatory conditions (Carpenter et al., 1995). Thus, the
lack of soluble TNFR2, which can scavenge TNF (Aderka
et al., 1992) and block its action, may result in stronger
TNFR1 signalling. In contrast, TNFR1–/– and TNFR1/
TNFR2–/– mice resemble the phenotype of TNF/LT-α mice
(Table 1). Both TNFRs are upregulated in the high endothelial
venules of the lymph nodes and the CNS during the preclinical
phase of EAE (Kahn et al., 1999). However, it is not known
whether the absence of one of the two TNFRs leads to altered
expression of the remaining receptor. Nevertheless, it is clear
that TNFR1 signalling is intact in TNFR2–/– mice (Peschon
et al., 1998). The chronic progressive disease, which
developed without being preceded by an acute phase, was
not associated with extensive demyelination but rather with
profound inflammation in the CNS at late (day 60 after
immunization) stages of disease (Eugster et al., 1999). This
inflammation was paralleled by a reduction in T-cell apoptosis
in cellular infiltrates (Bachmann et al., 1999). In TNFR1/
TNFR2–/– mice, inflammation was less striking than in
TNFR1–/– mice. Thus, demyelination in MOG-induced EAE
depends largely on TNFR1-mediated signalling. It remains
to be determined whether TNF-α, LT-α or a still unidentified
ligand of the TNFR1 is responsible for inducing this effect.
In contrast, the TNFR1 is not essential for the development
of CNS inflammation but plays a major role in the removal
of T cells from lesions, and it may therefore be involved in
disease resolution. The TNFR1 has been shown to play an
important role not only in EAE but also in other experimental
autoimmune diseases, such as collagen-induced arthritis
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(Mori et al., 1996), myosin-induced myocarditis (Bachmaier
et al., 1997) and autoimmune diabetes in NOD (nonobese
diabetic) mice (Pakala et al., 1999). These findings allocate
an important mediator function to TNFR1 in experimental
autoimmune disease.
TNFR1-dependent demyelination in mice
overexpressing TNF-α in the CNS
Potent roles for TNF-α/TNFR1 signalling in the pathogenesis
of CNS inflammation and primary demyelination have been
demonstrated further in another, non-autoimmune-mediated
model of multiple sclerosis in which disease is triggered
spontaneously by the local expression of murine or human
TNF-α transgenes by CNS glia. Two independent lines of
transgenic mice have been described. The Tg6074 line has a
high level of expression of a murine TNF-α transgene, under
the control of its own promoter, specifically in the CNS,
probably by virtue of the chance integration site of the
transgene into the murine genome. Expression of this
transgene was detectable from the first postnatal week of age
in immature glial precursor cells (Probert et al., 1995;
Akassoglou et al., 1998a). The TgK21 line shows astrocyte-
specific expression of a mutant human TNF-α transgene,
which leads to the production of an uncleavable,
transmembrane TNF protein under the control of the promoter
of the glial fibrillary acid protein gene (Akassoglou et al.,
1997). Both transgenic lines spontaneously develop
oligodendrocyte apoptosis, myelin vacuolation and primary
demyelination, which proceeds in the presence of large
numbers of T cells and recruited phagocytic macrophages
(Akassoglou et al., 1998a) (Fig. 2D). Lesions progress to
chronic (Tg6074) or acute (TgK21) multiple sclerosis-like
plaques, with secondary axonal damage. Clinical symptoms
differ in the two transgenic lines, and this is likely to reflect
differences in the site of transgene expression and therefore
the primary location of the lesions. Tg6074 mice, in which
the lesions affect mainly the white matter of the cerebellum,
develop ataxia between 3 and 4 weeks of age, followed by
kyphosis, limb paresis and paralysis (Probert et al., 1995).
TgK21 mice, which develop severe inflammatory lesions in
the spinal cord, show ascending paralysis similar to that seen
in EAE (Akassoglou et al., 1997). A dominant role for the
TNFR1 in signalling both inflammation and demyelination
in these models was demonstrated by the finding that disease
was completely abrogated when transgenic mice were
backcrossed onto a TNFR1-deficient background
(Akassoglou et al., 1998a) (Fig. 2E). A clue to the mechanism
by which TNF-α induces oligodendrocyte death has also
come from transgenic studies. Astrocyte-specific expression
of a biologically active, uncleavable membrane TNF-α
protein in transgenic mice selectively triggers oligo-
dendrocyte apoptosis and demyelination via TNFR1-
mediated signalling (Akassoglou et al., 1998a), even in
the absence of endogenous TNF-α (K. Akassoglou and
L. Probent, unpublished observations). In contrast, oligo-
dendrocytes remain completely unaffected by the neurone-
specific expression of membrane or wild-type (membrane
and soluble) TNF-α molecules in young animals, even
though CNS inflammation is severe in the latter case,
particularly in the meninges and perivascular space
(K. Akassoglou and L. Probent, unpublished observations).
Oligodendrocyte and myelin damage is observed only in
old animals. These results indicate that TNF-α/TNFR1-
mediated demyelination is mechanistically independent of
TNF-α/TNFR1-mediated CNS inflammation in vivo in
transgenic mice. Furthermore, they show that TNF-α can
mediate oligodendrocyte and myelin damage through cell
contact-dependent mechanisms involving membrane TNF-
α, when expressed as a transgene by appropriate cells
such as astrocytes. It remains to be determined, however,
whether this action of TNF-α is due to a direct effect on
oligodendrocytes or whether it is mediated by an indirect
mechanism mediated by TNFR1 on microglia/macrophages,
for example.
Therefore, in both TNF-α transgenic mice and MOG-
induced EAE, the TNFR1 has been found to be important
for the development of demyelination and the initiation of
the inflammatory process. In contrast to MOG-induced
EAE, CNS inflammation has also been shown to require
TNFR1 for its development and progression in TNF-α
transgenic mice. It is important to note here that the
contribution of inflammation to disease appears to be
completely different in these two models (Fig. 3). In EAE,
activated T cells drive disease and the TNFR1 is important
in mediating T-cell apoptosis within the CNS and clinical
remission once disease has been initiated (Bachmann et al.,
1999). In TNF-α transgenic mice, clinical symptoms and
histopathological changes develop independently of adaptive
immunity (Kassiotis et al., 1999b). Histopathological lesions
begin with TNFR1-dependent oligodendrocyte apoptosis.
Lesions progress to fulminant demyelinating plaques, and
in sharp contrast to EAE, remyelination does not occur.
In this latter model the multiple pro-inflammatory effects
of continuous TNF-α/TNFR1 signalling within the CNS,
for example in the activation of endothelial cells, astrocytes
and microglia/macrophages, appear to dominate a chronic–
progressive disease and vanish in the absence of TNFR1.
Disease induced by the murine TNF-α transgene in
Tg6074 mice developed fully in the absence of the TNFR2
(Akassoglou et al., 1998a). While the TNFR2 does not
appear to contribute significantly to pathology in the
Tg6074 system, we have recently obtained evidence
that transmembrane TNF-α expressed on astrocytes can
specifically signal pro-inflammatory effects through the
TNFR2 in the CNS of transgenic mice when this receptor
is overexpressed on a TNFR1–/– background. Specifically,
transmembrane TNF-α/TNFR2 interactions lead to endo-
thelial cell activation and the upregulation of adhesion
molecules, with the development of chronic vascular
inflammation and perivascular deposition of connective
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Fig. 3 Critical points in TNF/TNFR functioning in the pathogenesis of CNS inflammation and
demyelination, as understood from the study of animal models. Disease in EAE (right) is initiated and
driven by autoreactive T lymphocytes (T). Invasion of the CNS by activated T cells results in
breakdown of the blood–brain barrier (BBB), glial cell activation and local release of cytokines within
the CNS microenvironment. Primary demyelination is induced by different immune effector
mechanisms depending upon the genetic background of the animal and the antigen used, and involves
the phagocytosis of myelin by activated microglia and recruited blood monocytes (Mg/M). Primary
demyelination proceeds with little damage to the myelin-forming oligodendrocyte (OL) and with
maintenance of the potential for remyelination. Aberrant local TNF expression on the other hand, as it
occurs in TNF-transgenic mice (left), can induce oligodendrocyte apoptosis and myelin vacuolation, as
well as primary inflammatory demyelination, which may be initiated by the pro-inflammatory effects of
TNF on local CNS glia and endothelial cells. In this model, demyelination proceeds in the presence of
activated phagocytic Mg/Mφ, T and B cells, considerable oligodendrocyte depletion, and the absence of
remyelinating events. The pattern of demyelination observed in TNF transgenics closely resembles that
observed in a subgroup of multiple sclerosis patients whose lesions are characterized by primary
oligodendropathy (Lucchinetti et al., 1996).
tissue fibres (fibrosis), the latter representing a footprint of
the extensive and chronic inflammatory process (Akassoglou
et al., 1998b). This adds to previous evidence that the
TNFR2 is an important mediator of vascular inflammation,
as seen in the murine model of cerebral malaria (Lucas
et al., 1997), and indicates that under certain circumstances
TNF-α/TNFR2 interactions may contribute to CNS disease.
TNFR1, the ideal target for treatment?
TNF-α and LT-α have been implicated as key mediators in
chronic inflammatory and autoimmune diseases such as EAE
and multiple sclerosis, and have been identified as important
therapeutic targets for more than a decade. It is now clear,
through the study of this ligand/receptor family in vivo in
transgenic and knockout animals, that their diverse and potent
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effects in the pathogenesis of disease extend well beyond
their long-established pro-inflammatory effects. This newly
emerging evidence is expected to have a significant impact
upon the design of any therapeutic protocols that aim to block
TNF/LT-α signalling pathways or downstream mediators for
the treatment of human autoimmune diseases such as multiple
sclerosis.
A critical role for TNF-α in the initiation of the neurological
deficits of EAE and in leucocyte movement within the CNS
has been defined, specifically in the formation of perivascular
cuffs (Korner et al., 1997a). An important role for TNF-α
in orchestrating cell movement is also manifest in the
altered splenic architecture that characterizes TNF-α–/– mice
(Appendix I). TNF-α is known to induce the expression
of adhesion molecules (Bevilacqua, 1993) and chemokines
(Butcher and Picker, 1996), and both types of molecule
are potentially important secondary mediators of TNF-α-
dependent effects on cell movement. Consistent with this
concept, recent evidence has shown that the production of
T- and B-cell chemoattractants is reduced in the spleen and
lymph nodes of TNF-α–/– and LT-α/β–/– mice (Appendix I)
(Ngo et al., 1999). It will be interesting to identify such
TNF-α-inducible molecules from the CNS during EAE.
Furthermore, a potent anti-inflammatory role during EAE
has been ascribed to TNF-α, following the observation that
neurological signs of disease are significantly increased in
its absence (Liu et al., 1998). A variety of TNF-α-dependent
processes may underlie this effect. For example, there is
good evidence to show that TNF-α can downregulate systemic
and organ-specific autoimmunity and that T cells are
important targets (Appendix I). Although the mechanisms
behind this effect are not yet known, there is recent evidence
that TNF-α can attenuate T-cell receptor signalling.
Alternatively, TNF-α may signal apoptosis directly in
activated CD4 and CD8 cells in vivo. Indeed, a major role
for the TNFR1 in inducing T-cell apoptosis and lymphocyte
clearance from the CNS during EAE, and therefore in
the limitation of disease, has been demonstrated recently
(Bachmann et al., 1999).
Finally, studies in TNF-α transgenic mice clearly show
that TNF-α/TNFR1 signalling can induce oligodendrocyte
apoptosis, myelin vacuolation and primary, macrophage-
mediated demyelination (Akassoglou et al., 1998a).
Unfortunately, quantitative data concerning experimentally
induced demyelination in TNF-α–/– mice are not yet available,
but MOG-induced demyelination in TNFR1–/– mice is
significantly reduced (Eugster et al., 1999), indicating that
this signalling pathway is also critically involved in
demyelination in EAE. It remains to be determined whether
TNF-α, LT-α or an as yet unidentified ligand of the TNFR1
signals this effect. Nevertheless, the finding that
demyelination can proceed even in the absence TNF-α/
TNFR1 signalling in the EAE model shows that alternative
pathways exist to mediate this process. In MOG-immunized
TNF/LT-α–/– mice, initially generated on the 129/Sv 
C57BL/6 (H-2b) genetic background, backcrossed to SJL/J
(H-2s) mice, the extent of demyelination and inflammation
was greater, equivalent to that seen in wild-type mice of the
C57BL/6 background (Frei et al., 1997). Since TNF/LT-α–/–
SJL mice carried the MHC H-2b haplotype from the parental
C57BL/6 mice, these results indicate that non-MHC genes
in SJL mice compensate for the absence of TNF-α and LT-
α in mediating demyelination. The importance of non-
MHC genes in mediating EAE in SJL mice has also been
demonstrated in MBP-induced EAE, in which a comparison
between SJL/J inbred mice and SJL H-2b mice [generated as
congenic controls for TNF-α–/– mice (H-2b) that had been
backcrossed for five generations onto SJL], showed no
difference in the development of neurological deficits,
inflammation or demyelination despite the presence of a non-
susceptible haplotype (H-2b) in the latter mice (Kassiotis et al.,
1999b). Identification of the genes that link inflammation with
demyelination in MOG-induced EAE in TNF/LT-α–/– SJL
mice might open new avenues of experimental therapy in
EAE. Linkage analysis of crosses between EAE susceptible
SJL/J (H-2s) and resistant B10s (H-2s) mice revealed disease
susceptibility loci at the telomeric end of chromosome 2 and
near the centre of chromosome 3 (Encinas et al., 1996).
However, these loci were found to map with inflammatory
loci and clinical disease. It will be interesting to take
demyelination as a readout in genetic studies in the future.
With the increased understanding of the roles of TNFR1-
mediated signalling in leucocyte recruitment into the CNS,
demyelination and T-cell apoptosis and clearance, potential
selective applications of soluble TNFR1 in multiple sclerosis
can be envisaged. Indeed, in EAE, the parenteral
administration of TNFR1 inhibits the development of
neurological deficits in Lewis rats and SJL/J mice immunized
with MBP (Martin et al., 1995; Selmaj et al., 1995; Klinkert
et al., 1997; Korner et al., 1997b) if treatment is before
the onset of clinical disease. This is consistent with the
demonstrated role of TNF-α in the initiation of CNS
inflammation. However, established disease is relatively
refractory to this treatment. A recent multicentre study on
multiple sclerosis patients with relapsing–remitting disease
treated with TNFR1 had to be stopped because of a significant
increase in the frequency of relapse (Van Osten et al., 1996).
In the light of recent finding that, in multiple sclerosis
patients, various subgroups can be found with apparently
different mechanisms of demyelination (Lucchinetti et al.,
1996), it is perhaps not surprising that TNF blockade did
not give the expected results. Moreover, with our present
knowledge of the role of TNFR1 in the clearance of T cells
from the CNS and in disease limitation, it is clear that any
treatment aimed at blocking the action of TNF would need
to be selective. A combination of soluble TNFR treatment
with antagonists that block the adherence of T cells or their
trafficking through the blood–brain barrier, for example
inhibitors of matrix metalloproteases, is more likely to
influence disease activity. Nonetheless, the identification
of the non-MHC genes that influence TNFR1-independent
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demyelination, as seen in SJL mice, is expected to open
exciting new opportunities for therapy in multiple sclerosis.
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Appendix I
The MHC-encoded cytokines, tumour necrosis factor α (TNF-α)
and lymphotoxin α (LT-α) (Gray et al., 1984; Nedwin et al., 1985;
Pennica et al., 1985; Nedospasov et al., 1986), are proinflammatory,
cytotoxic cytokines and critical mediators of host defence and
immune regulation (Vassalli, 1992). TNF-α is expressed in response
to injury or infection by a wide variety of haematopoietic and non-
haematopoietic cells, mainly macrophages. It is produced as a
26 kDa membrane-associated protein which is cleaved and released
as a soluble 17 kDa protein by specific metalloproteinases (Black
et al., 1997; Moss et al., 1997) (Fig. A1). Both the soluble 17 kDa
and the cell-associated 26 kDa molecular forms of TNF-α trimerize
to form the bioactive ligand. They signal through two structurally
related but functionally distinct receptors, the TNFR1 (p55 TNF-α
receptor) and the TNFR2 (p75 TNF-α receptor), that are coexpressed
on most cell types, to initiate and regulate cell death and survival
pathways (Vandenabeele et al., 1995). TNF-α mediates functions
that range from the recruitment of leucocytes at sites of inflammation
to the regulation of cell death by proliferation, cytotoxicity or
apoptosis (Wallach et al., 1997). The complexity of the action of
TNF-α in vivo reflects factors such as the differential presence and
activity of the soluble 17 and 26 kDa molecular forms, independent
signalling by the TNFR1 and TNFR2, and the availability of
shedded receptors which neutralize or augment TNF-α action. The
majority of biological responses classically attributed to TNF-α are
mediated by TNFR1. In contrast, TNFR2 has few specific functions;
these include the induction of thymocyte proliferation in vitro
and possibly a role in suppressing TNF-α-mediated inflammatory
responses in vivo (Peschon et al., 1998). LT-α is expressed as a 25
kDa protein (Ware et al., 1995). It has no transmembrane sequence
but is functional either as a soluble homotrimer (LT-α3) or in
association with LTβ (LT-α1β2) on the surface of activated T and
B cells and NK cells. Although TNF-α and the secreted form of
LT-α (LT-α3) share receptors, they are produced by different types
of cells in response to different stimuli, and despite similarity in
their binding affinity to TNF-α receptors, the cellular responses to
binding appear to be different (Schuchmann et al., 1995). The two
cytokines therefore function as distinct entities in vivo. LT-α1β2
heterotrimers have been shown recently to signal specifically through
a distinct receptor, the LT-βR (Crowe et al., 1994), and this is now
known to mediate distinct functional effects in vivo.
TNF-α and LT-α have been shown to be critical mediators of
immune function and host defence (antiviral and antibacterial).
Studies in gene-targeted mice deficient in the TNF-α/LT-α ligand
and receptor system have revealed essential functions for these
cytokines in the development and organization of lymphoid tissue
and in immune function, and have shown that the effects of
of exogenous cytokines using a recombinant vaccinia virus system.
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TNF-α and LT-α are largely non-overlapping. LT signalling through
the LT-βR is crucial for the organogenesis of lymph nodes and
Peyer’s patches, the development of normal spleen structure and
the maturation of antibody affinity (De Togni et al., 1994; Matsumo
et al., 1996; Futterer et al., 1998). In contrast, lymphoid organo-
genesis in TNF-α and TNFR1 knockout mice remains intact, but
these molecules are essential for the correct formation of splenic
follicular structures and germinal centres, and B-cell follicles in all
secondary lymphoid tissues (Le Hir et al., 1996; Pasparakis et al.,
1996, 1997; Alimzhanov et al., 1997; Alexopoulou et al., 1998).
Recent evidence indicates that these effects of TNF-α and of LT-α
signalling through the LT-βR on B- and T-cell organization are
mediated by the downstream induction of chemokines such as B-
lymphocyte chemoattractant (BCL) and secondary lymphoid tissue
chemokine (SLC) from stromal cells (Ngo et al., 1999). Comparative
studies have indicated that LT-α3 may signal independently of
LT-β in the development of mesenteric and cervical lymph nodes
(Rothe et al., 1993; Ngo et al., 1999). Moreover, TNF-α and TNFR1
signalling is central to the successful host defence response to
infection by various pathogens (Flynn et al., 1995; Marino et al.,
1997), and a specific role for TNF-α/TNFR2 signalling in the
inhibition of the entry of HIV-1 into human primary tissue-cultured
macrophages has been shown (Herbein et al., 1996).
In contrast to their essential roles in lymphoid organ development
and their beneficial effects during infection and tumorigenesis
(Vassalli, 1992), TNF-α and LT-α have well-documented
proinflammatory effects and have been implicated directly in the
pathogenesis of human inflammatory and autoimmune diseases.
Studies in knockout mice have shown that TNFR1 is a key mediator
of endotoxic shock, and there is now considerable evidence to show
that the overproduction or inappropriate production of TNF-α and
LT-α, or the membrane accumulation of TNFR1, can be deleterious
to the host and linked with the pathogenesis of distinct human
diseases such as rheumatoid arthritis and multiple sclerosis (Raine,
1995; Korner and Sedgwick, 1996; McDermott et al., 1999).
Interestingly, TNFR2 has been shown recently to signal ligand-
independent pathology when overexpressed in transgenic mice
(Douni and Killias, 1998). Both TNF-α and LT-α can influence
disease at multiple levels. They are potently proinflammatory and
their overexpression in transgenic or mutant mice triggers local
inflammation and the development of complex disease phenotypes
such as arthritis and Crohn’s-type disease (Kratz et al., 1996;
Kontoyiannis et al., 1999). TNF-α and LT-α are also cytotoxic
cytokines, and by triggering death in target cells such as
oligodendrocytes (Selmaj and Raine, 1988) may initiate and
exacerbate inflammation and autoimmunity. Finally, there is now
compelling evidence to suggest that chronic TNF-α expression
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Fig. A1 TNF-α, LT-α and their receptors. TNF-α is produced as a 26 kDa membrane-associated
protein (mTNF), which is cleaved and released as a soluble 17 kDa protein (sTNF) by specific
metalloproteinases, such as TNF-α-converting enzyme (TACE). Both forms of TNF-α, and LT-α,
signal as trimers through the TNFR1 and TNFR2 to mediate cell apoptosis or cell activation and/or
proliferation involving nuclear factor-kappa B (NF-κB) activation. LT-α can also form heterocomplexes
with membrane-associated LT-β and signal through the distinct LT-βR to mediate similar cellular
consequences, although the upstream components of the LT-βR-mediated signalling pathways remain to
be identified.
in vivo leads to unique regulatory properties that target the adaptive
immune response and appear to be beneficial to the host (Cope,
1998). TNF-α can suppress the progression of systemic (Jacob
et al., 1990) and organ-specific (Grewal et al., 1996; McSorley
et al., 1997) autoimmune diseases in vivo, and disease suppression is
associated with depressed antigen-specific T-cell responses. Several
mechanisms for these suppressive effects have been proposed,
including the attenuation of T-cell receptor signalling (Cope et al.,
1997) and the induction of functional immunological tolerance
(McSorley et al., 1997). TNF-α can also induce apoptosis of CD8
and CD4 T cells in vivo (Zheng et al., 1995; Sytwu et al., 1996)
and thereby may contribute to FasL/Fas-mediated signalling in the
elimination of autoreactive T cells. The specific contributions of
LT-α signalling through the TNF-α receptors and LTβR to the
pathogenesis of inflammatory and autoimmune disease remain to
be investigated.
Considering the intricate involvement of the TNF-α ligand and
receptor family members in multiple physiological and
pathophysiological processes, it is not surprising that the targeting
of these molecules represents a powerful and modern therapeutic
approach for the treatment of several human diseases. TNF-α
blockade has already proved beneficial in the treatment of rheumatoid
arthritis (Elliott et al., 1994) and Crohn’s disease (van Dullemen
et al., 1995), and may prove useful in the immune targeting of
tumours. On the other side of the coin, the full potential of the
beneficial effects of TNF-α, for example in mediating haemorrhagic
necrosis in certain tumours and the suppression of autoimmunity,
has yet to be exploited.
